Mavenclad
NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic
March 3, 2021Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis
NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …
NHS England seals access deals with big pharma for breast cancer and MS
November 9, 2017Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …
Seven years later, EC gives approval for Merck KGaA’s MS drug
August 25, 2017Medical Communications, Sales and Marketing Mavenclad, Merck KGaA, biotech, drugs, multiple sclerosis, pharma, pharmaceutical
In 2011, Merck KGaA had all but given up on its MS drug after having been knocked back by both …
